Johnson & Johnson

JNJ-N

NYSE:JNJ

145.24
0.16 (0.11%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia

Analysis and Opinions about JNJ-N

Signal
Opinion
Expert
BUY
BUY
March 17, 2004
There is competition in the stent market. The whole health-care sector is a bit of a puzzle. Has been executing very well, but money just doesn't seem to want to flow into health-care.
Show full opinionHide full opinion
There is competition in the stent market. The whole health-care sector is a bit of a puzzle. Has been executing very well, but money just doesn't seem to want to flow into health-care.
TOP PICK
TOP PICK
March 5, 2004
One of a handful of AAA Company's out there. Great dividend history. Reasonable P/E valuation. Hasn't participated in the strong market over the course of the last year or so.
Show full opinionHide full opinion
One of a handful of AAA Company's out there. Great dividend history. Reasonable P/E valuation. Hasn't participated in the strong market over the course of the last year or so.
TOP PICK
TOP PICK
March 5, 2004
A non cyclical stock. Pays a dividend yield in the healthcare sector.
Show full opinionHide full opinion
A non cyclical stock. Pays a dividend yield in the healthcare sector.
HOLD
HOLD
December 23, 2003
They've been groeing their market share by 20% throughout the last 4 years. Trading at evaluation standards that are fantastic, looks attractive for long-term hold, Drug companies are undervalued., could see some good gains.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
December 23, 2003
They've been groeing their market share by 20% throughout the last 4 years. Trading at evaluation standards that are fantastic, looks attractive for long-term hold, Drug companies are undervalued., could see some good gains.
BUY
BUY
December 12, 2003
In the long term, it's a great diversified play in the healthcare sector.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
December 12, 2003
In the long term, it's a great diversified play in the healthcare sector.
DON'T BUY
DON'T BUY
December 5, 2003
Has been stuck around $50 mark. Took a big jump when they first produced a stent but they now have competition, which is taking quite a bit of market share. Could see it go a bit lower.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
December 5, 2003
Has been stuck around $50 mark. Took a big jump when they first produced a stent but they now have competition, which is taking quite a bit of market share. Could see it go a bit lower.
TOP PICK
TOP PICK
October 27, 2003
A contrarian play. Has performed very well from a financial perspective. Growth prospect is a very positive. Very good long-term value.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 27, 2003
A contrarian play. Has performed very well from a financial perspective. Growth prospect is a very positive. Very good long-term value.
BUY
BUY
August 27, 2003
Trading at a discounted valuation. They are getting competition with their stents. At a decent valuation. Should see some upside from here.
Show full opinionHide full opinion
Trading at a discounted valuation. They are getting competition with their stents. At a decent valuation. Should see some upside from here.
BUY
BUY
August 22, 2003
Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.A good price to buy out for the long-term.
Show full opinionHide full opinion
Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.A good price to buy out for the long-term.
BUY
BUY
August 20, 2003
They have a huge consumer business.The drug sector has been sluggish.Longer term this should pick up.
Show full opinionHide full opinion
They have a huge consumer business.The drug sector has been sluggish.Longer term this should pick up.
WEAK BUY
WEAK BUY
June 30, 2003
Book value is about $8 a share. Drug companies always seem to do well.
Show full opinionHide full opinion
Book value is about $8 a share. Drug companies always seem to do well.
BUY
BUY
May 16, 2003
Stable growth. Valuation may be a little high, but OK.
Show full opinionHide full opinion
Stable growth. Valuation may be a little high, but OK.
DON'T BUY
DON'T BUY
January 13, 2003
A defensive stock, so could lag a bit.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
January 13, 2003
A defensive stock, so could lag a bit.
BUY
BUY
December 6, 2002
Great company. Into stents now which will be a big market opportunity.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
December 6, 2002
Great company. Into stents now which will be a big market opportunity.
BUY
BUY
October 23, 2002
Well rounded in different health areas.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 23, 2002
Well rounded in different health areas.
Showing 421 to 435 of 460 entries